m6A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer

被引:173
作者
Chong, Wei [1 ,2 ,3 ]
Shang, Liang [1 ,2 ,3 ]
Liu, Jin [4 ]
Fang, Zhen [2 ,3 ]
Du, Fengying [2 ,3 ]
Wu, Hao [2 ,3 ]
Liu, Yang [2 ,3 ]
Wang, Zhe [5 ]
Chen, Yang [6 ,7 ,8 ]
Jia, Shengtao [9 ]
Chen, Liming [10 ]
Li, Leping [1 ,2 ,3 ]
Chen, Hao [11 ]
机构
[1] Shandong First Med Univ, Shandong Prov Hosp, Dept Gastrointestinal Surg, Jinan 250021, Shandong, Peoples R China
[2] Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Gastrointestinal Surg, Jinan 250021, Shandong, Peoples R China
[3] Shandong Prov Hosp, Key Lab Engn Shandong Prov, Jinan 250021, Shandong, Peoples R China
[4] Shandong Prov Hosp, Dept Gastroenterol, Key Lab Engn Shandong Prov, Jinan 250021, Shandong, Peoples R China
[5] Tianjin Sino US Diagnost Co Ltd, Tianjin, Peoples R China
[6] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Radiat Oncol, Tianjin, Peoples R China
[7] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[8] Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[9] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Tumor Cell Biol, Tianjin, Peoples R China
[10] Harvard Univ, Ctr Adv Biomed Imaging & Photon, Beth Israel Deaconess Med Ctr, Div Gastroenterol,Dept Med, Boston, MA 02215 USA
[11] Shandong Univ, Qilu Hosp, Clin Res Ctr, Clin Epidemiol Unit, Jinan 250021, Shandong, Peoples R China
来源
THERANOSTICS | 2021年 / 11卷 / 05期
关键词
Colon cancer; m(6)A modification; Tumor microenvironment; Immune profiles; Immunotherapy; COLORECTAL-CANCER; CHECKPOINT BLOCKADE; IMMUNOPHENOTYPE; SIGNATURE; HALLMARKS; CELLS;
D O I
10.7150/thno.52717
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Recent studies have highlighted the biological significance of RNA N-6-methyladenosine (m(6)A) modification in tumorigenicity and progression. However, it remains unclear whether m(6)A modifications also have potential roles in immune regulation and tumor microenvironment (TME) formation. Methods: In this study, we curated 23 m(6)A regulators and performed consensus molecular subtyping with NMF algorithm to determine m(6)A modification patterns and the m(6)A-related gene signature in colon cancer (CC). The ssGSEA and CIBERSORT algorithms were employed to quantify the relative infiltration levels of various immune cell subsets. An PCA algorithm based m(6)Sig scoring scheme was used to evaluate the m(6)A modification patterns of individual tumors with an immune response. Results: Three distinct m(6)A modification patterns were identified among 1307 CC samples, which were also associated with different clinical outcomes and biological pathways. The TME characterization revealed that the identified m(6)A patterns were highly consistent with three known immune profiles: immune-inflamed, immune-excluded, and immune-desert, respectively. Based on the m(6)Sig score, which was extracted from the m(6)A-related signature genes, CC patients can be divided into high and low score subgroups. Patients with lower m(6)Sig score was characterized by prolonged survival time and enhanced immune infiltration. Further analysis indicated that lower m(6)Sig score also correlated with greater tumor mutation loads, PD-L1 expression, and higher mutation rates in SMGs (e.g., PIK3CA and SMAD4). In addition, patients with lower m(6)Sig scores showed a better immune responses and durable clinical benefits in three independent immunotherapy cohorts. Conclusions: This study highlights that m(6)A modification is significantly associated with TME diversity and complexity. Quantitatively evaluating the m(6)A modification patterns of individual tumors will strengthen our understanding of TME characteristics and promote more effective immunotherapy strategies.
引用
收藏
页码:2201 / 2217
页数:17
相关论文
共 81 条
  • [1] Understanding the tumor immune microenvironment (TIME) for effective therapy
    Binnewies, Mikhail
    Roberts, Edward W.
    Kersten, Kelly
    Chan, Vincent
    Fearon, Douglas F.
    Merad, Miriam
    Coussens, Lisa M.
    Gabrilovich, Dmitry I.
    Ostrand-Rosenberg, Suzanne
    Hedrick, Catherine C.
    Vonderheide, Robert H.
    Pittet, Mikael J.
    Jain, Rakesh K.
    Zou, Weiping
    Howcroft, T. Kevin
    Woodhouse, Elisa C.
    Weinberg, Robert A.
    Krummel, Matthew F.
    [J]. NATURE MEDICINE, 2018, 24 (05) : 541 - 550
  • [2] Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer
    Borcoman, Edith
    De La Rochere, Philippe
    Richer, Wilfrid
    Vacher, Sophie
    Chemlali, Walid
    Krucker, Clementine
    Sirab, Nanour
    Radvanyi, Francois
    Allory, Yves
    Pignot, Geraldine
    de Longchamps, Nicolas Barry
    Damotte, Diane
    Meseure, Didier
    Sedlik, Christine
    Bieche, Ivan
    Piaggio, Eliane
    [J]. ONCOIMMUNOLOGY, 2019, 8 (05):
  • [3] Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence
    Camus, Matthieu
    Tosolini, Marie
    Mlecnik, Bernhard
    Pages, Franck
    Kirilovsky, Amos
    Berger, Anne
    Costes, Anne
    Bindea, Gabriela
    Charoentong, Pornpimol
    Bruneval, Patrick
    Trajanoski, Zlatko
    Fridman, Wolf-Herman
    Galon, Jerome
    [J]. CANCER RESEARCH, 2009, 69 (06) : 2685 - 2693
  • [4] Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
    Charoentong, Pornpimol
    Finotello, Francesca
    Angelova, Mihaela
    Mayer, Clemens
    Efremova, Mirjana
    Rieder, Dietmar
    Hackl, Hubert
    Trajanoski, Zlatko
    [J]. CELL REPORTS, 2017, 18 (01): : 248 - 262
  • [5] Elements of cancer immunity and the cancer-immune set point
    Chen, Daniel S.
    Mellman, Ira
    [J]. NATURE, 2017, 541 (7637) : 321 - 330
  • [6] Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer
    Chen, Hao
    Chong, Wei
    Yang, Xiaorong
    Zhang, Yuan
    Sang, Shaowei
    Li, Xiangchun
    Lu, Ming
    [J]. ONCOIMMUNOLOGY, 2020, 9 (01):
  • [7] The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma
    Chen, Hao
    Yang, Meng
    Wang, Qinghua
    Song, Fengju
    Li, Xiangchun
    Chen, Kexin
    [J]. ONCOIMMUNOLOGY, 2019, 8 (08):
  • [8] The immune response-related mutational signatures and driver genes in non-small-cell lung cancer
    Chen, Hao
    Chong, Wei
    Teng, Changcai
    Yao, Yueliang
    Wang, Xin
    Li, Xue
    [J]. CANCER SCIENCE, 2019, 110 (08) : 2348 - 2356
  • [9] A Convenient and Robust Test to Quantify Interocular Suppression for Children With Amblyopia
    Chen, Hui
    He, Zhifen
    Xu, Jinling
    Mao, Yu
    Liang, Yunjie
    Lin, Danli
    Xu, Meiping
    Dai, Zhiyue
    Chen, Xiaoxin
    Zhou, Jiawei
    Yu, Xinping
    [J]. I-PERCEPTION, 2019, 10 (04):
  • [10] The role of m6A RNA methylation in human cancer
    Chen, Xiao-Yu
    Zhang, Jing
    Zhu, Jin-Shui
    [J]. MOLECULAR CANCER, 2019, 18 (1)